New Era Energy & Digital Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $3.38 (market cap $518.22M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 2.9× New Era Energy & Digital Inc. Common Stock's market cap, and New Era Energy & Digital Inc. Common Stock is more actively traded (7,267,523 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 2 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NUAI | QURE | |
|---|---|---|
Market Cap | $518.22M | $1.48B |
Volume | 7,267,523 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $8.06 | $70.59 |
52-Week Low | $2.37 | $9.03 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $463.57M | $728.62M |
Signals from Pluang's Aura AI — not financial advice
NUAI trades at $4.29, down 1.15% today, with a bearish technical signal despite recent positive news about a 20-year power deal for its Texas data center project. The company shows severe financial stress with negative margins (-5,985.71% net income margin) and consecutive quarterly losses, though analyst consensus remains bullish with a $10.67 price target. Recent institutional interest includes BlackRock's new stake in Q2 2026.
The stock presents high-risk speculation with potential upside if data center development succeeds, but faces substantial execution and funding risks. Current fundamentals are weak, making it suitable only for risk-tolerant investors betting on future project milestones and hyperscaler partnerships.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →